Patents by Inventor Zhongxiang Zhou

Zhongxiang Zhou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11548900
    Abstract: Provided are an oxazino-quinazoline and oxazino-quinoline type compound, a preparation method, and uses thereof. More particularly provided is a compound shown in formula (I), an isomer, a hydrate, a solvate, a pharmaceutically acceptable salt, a prodrug thereof, a preparation method, and uses thereof in preparing a drug acting as a kinase inhibitor.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: January 10, 2023
    Assignee: BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED
    Inventors: Qiang Zhang, Shannan Yu, Zhongxiang Wang, Shouye Feng, Nanqiao Zheng, Hailong Yang, Leifu Yang, Hongbo Zhang, Likai Zhou, Zhanqiang Xu
  • Patent number: 11479559
    Abstract: The present invention relates to an urea-substituted aromatic ring-linked dioxinoquinoline compound of formula (I), or a pharmaceutically acceptable salt or a hydrate thereof. The invention also provides a preparation method of the compound of formula (I) and a pharmaceutically acceptable salt thereof, as well as uses thereof as a drug, wherein the drug acting as a tyrosine kinase (i.e. VEGFR-2, C-RAF, B-RAF, and RET) inhibitor is used for treating disorders related to tyrosine kinase.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: October 25, 2022
    Assignee: BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED
    Inventors: Qiang Zhang, Shannan Yu, Zhongxiang Wang, Shouye Feng, Yansheng Liu, Xingfu Li, Hongbo Zhang, Leifu Yang, Hailong Yang, Likai Zhou, Nanqiao Zheng, Chenming Hu, Zhanqiang Xu
  • Patent number: 11407760
    Abstract: The present invention relates to a dioxinoquinoline compound of formula (I) or a pharmaceutically acceptable salt thereof. The invention also provides a preparation method of the compound of formula (I) and a pharmaceutically acceptable salt thereof, as well as uses thereof as a drug, wherein the drug acting as a tyrosine kinase (i.e. VEGFR-2 and c-MET) inhibitor is used for treating disorders related to tyrosine kinase.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: August 9, 2022
    Assignee: BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED
    Inventors: Qiang Zhang, Shannan Yu, Zhongxiang Wang, Shouye Feng, Yueming Sun, Yansheng Liu, Hongbo Zhang, Leifu Yang, Hailong Yang, Likai Zhou, Nanqiao Zheng, Chenming Hu, Zhanqiang Xu
  • Publication number: 20100256357
    Abstract: Sulfonamides and pharmaceutical compositions containing the compounds useful in controlling intraocular pressure are disclosed. Methods for controlling intraocular pressure through administration of the compositions are also disclosed.
    Type: Application
    Filed: July 30, 2007
    Publication date: October 7, 2010
    Inventors: Wesley Kwan Mung Chong, Andrew M. Haidle, Martha Alicia Ornelas, Lin Li, Seiji Nukui, Eugene Yuanjin Rui, Min Teng, William Francois Vernier, Joe Zhongxiang Zhou
  • Publication number: 20090215742
    Abstract: The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts and solvates thereof, their synthesis, and their use as HSP-90 inhibitors.
    Type: Application
    Filed: April 21, 2006
    Publication date: August 27, 2009
    Inventors: Lee Andrew Funk, Mary Catherine Johnson, Pei-Pei Kung, Zhongxiang Zhou